Peggy Peck

UROLOGY ASSOCIATES OF DOVER

200 BANNING ST

SUITE 250

Articles

Entacavir (Baraclude) Gets Boxed Warning About HIV Resistance

August 17, 2007

ROCKVILLE, Md. -- The FDA has added a boxed warning to the litany of cautions about the use of entacavir (Baraclude), a hepatitis B drug, for certain patients co-infected with HIV.

Boxed Heart Failure Warning Added to Two Diabetes Drugs

August 14, 2007

ROCKVILLE, Md. -- The makers of rosglitazone (Avandia) and pioglitazone (Actos), have agreed to add a black box warning to the type 2 diabetes drugs' labels about an increased risk of heart failure, the FDA said today.

FDA Warns Against Use of Red Yeast Rice Supplements

August 10, 2007

ROCKVILLE, Md. -- The FDA has warned consumers against using three brands of red yeast rice, a product marketed as a natural remedy for high cholesterol, because they may contain lovastatin, the active ingredient in Mevacor.

Vibiriosis Outbreak Prompts FDA Raw Oyster Warning

August 10, 2007

ROCKVILLE, Md. -- Raw oyster harvested from a bed off the coast of Washington State have been linked to six reports of Vibrio parahaemolyticus illness, prompting an FDA warning.

Botulism Toxin Prompts Canned Green Bean Recall

August 03, 2007

ROCKVILLE, Md. -- For the second time in as many weeks, the FDA has issued a botulism toxin warning; this time the product is 14.5 ounce cans of French cut green beans manufactured by a Wisconsin food processor.

FDA Advisers Endorse Natalizumab (Tysabri) for Crohn's Disease

August 02, 2007

GAITHERSBURG, Md. -- FDA advisers have recommended approval of the problem-ridden multiple sclerosis drug natalizumab (Tysabri) for treatment of moderate to severe Crohn's disease, but only with extensive safety monitoring.

BREAKING NEWS: FDA Advisers Recommend Diabetes Drug Stay on Market

July 30, 2007

Gaithersburg, Md. -- By a vote of 20 to three a group of FDA advisers found evidence that rosiglitazone (Avandia), the popular oral anti-diabetes drug, increases the risk of myocardial infarction. But the same advisers said the drug should stay on the market.

FDA Advisers Recommend Raloxifene (Evista) for Prevention of Breast Cancer

July 25, 2007

ROCKVILLE, Md. - An FDA advisory panel has recommended that the agency approve raloxifene (Evista) for prevention of breast cancer in high-risk postmenopausal women.

Grand Jury Refuses to Indict New Orleans Doctor Charged with Killing Katrina-Stranded Patients

July 25, 2007

NEW ORLEANS -- Almost two years after Hurricane Katrina ravaged this city, a grand jury here refused to indict Anna M. Pou, M.D., in the deaths of four elderly patients at Memorial Medical Center.

Residents' Work-Hour Restrictions Shift Burden to Faculty Members

July 24, 2007

ROCHESTER, Minn. -- The old guard in medical education who predicted that shortened work hours for residents would lead to shoddy training of young physicians are claiming vindication.